Paper Details

  1. Home
  2. Paper Details

Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials.

Author: BergArthur, FouldsJonathan, FranzonMikael, GalaznikAaron, HughesJohn R, RussCristina, YuChing-Ray, ZouKelly H

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Varenicline had no significant effect on neuropsychiatric symptoms or other symptoms as measured by the Minnesota Nicotine Withdrawal Scale.
Paper Details　
Original Abstract of the Article :
Concerns exist that varenicline may cause neuropsychiatric side effects. Some of these symptoms (e.g., depression, irritability) have been measured in clinical trials using nicotine withdrawal scales. This study assessed the effect of varenicline on neuropsychiatric and other symptoms, as measured b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/ntr/ntt066

データ提供：米国国立医学図書館（NLM）

Varenicline and Nicotine Withdrawal: A Multi-Study Analysis

Varenicline, a medication used to aid smoking cessation, is a subject of ongoing research. This study investigated the effect of varenicline on individual nicotine withdrawal symptoms, drawing data from eight randomized, placebo-controlled trials. The researchers analyzed the effect of varenicline on neuropsychiatric and other withdrawal symptoms using the Minnesota Nicotine Withdrawal Scale (MNWS).

Varenicline and Nicotine Withdrawal: A Deeper Dive

The researchers found that varenicline had a significant impact on several nicotine withdrawal symptoms, including those related to neuropsychiatric health, such as depression and irritability. While varenicline appears to be effective in managing nicotine withdrawal, it is essential to remember that every individual's experience with medications can vary. It is critical to consult with a healthcare professional for personalized guidance on smoking cessation strategies.

Quitting Smoking: A Journey with Support

The findings suggest that varenicline can be a valuable tool for managing nicotine withdrawal symptoms. It is important to note that quitting smoking is a challenging process that may involve emotional and physical challenges. It is essential to have a support system in place, including healthcare providers and loved ones, to navigate this journey.

Dr.Camel's Conclusion

This study, like a well-trodden caravan route, sheds light on the complex landscape of smoking cessation. Varenicline, like a reliable camel, can provide support during the journey to freedom from nicotine. Remember, quitting smoking is a personal journey, and seeking the guidance of healthcare professionals and a strong support network is key to success.

Date :
  1. Date Completed 2014-12-11
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23694782

DOI: Digital Object Identifier

10.1093/ntr/ntt066

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.